Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

TA Repeat Polymorphism of the 5α-Reductase Gene and Breast Cancer

Bhupinder Bharaj, Andreas Scorilas, Maurizia Giai and Eleftherios P. Diamandis
Bhupinder Bharaj
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Scorilas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maurizia Giai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleftherios P. Diamandis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Representative DNA fragment analysis of three patients and one molecular weight standard run (last lane). The various TA length alleles are shown. The first patient is heterozygous (TA)0/(TA)9. Numbers below peaks, PCR product length in bp.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Distribution of TA genotypes in DNA from breast carcinomas and in DNA from leukocytes from females without breast cancer. As determined by the χ2 test, the differences were not statistically significant (P = 0.15). (TA)0, no TA repeats present; (TA)9, nine TA repeats present in the 3′ untranslated region of the SRD5A2 gene.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Relationship between TA genotypes and breast tumor extract PSA concentrations. ——, mean value. The medians were 7.1 ng/g and 10.2 ng/g for (TA)0 and (TA)0/(TA)9 or (TA)9 genotypes, respectively; P = 0.041, as determined by the Mann-Whitney U test.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    DFS (A) and OS (B) curves in breast cancer patients with TA0 and (TA)0/(TA)9 or (TA)9 genotypes, respectively. Vertical tick marks, the censored cases. Differences between genotypes were determined by log-rank tests.

Tables

  • Figures
  • Table 1

    Associations of TA genotypes with features of breast cancer

    FeaturesTotal patientsNo. of patients (%)P
    (TA)0(TA)0/(TA)9, (TA)9
    Age (yr)
    <453523 (24.5)12 (25.5)
    45–553622 (23.4)14 (29.8)0.65a
    >557049 (52.1)21 (44.7)
    Tumor size (cm)
    <24026 (28.3)14 (30.4)0.47b
    ≥29866 (71.7)32 (69.6)
    Nodal status
    Negative5231 (34.8)21 (45.6)0.10b
    Positive8358 (65.2)25 (54.4)
    Gradec
    I–II6144 (65.7)17 (53.1)0.16b
    III3823 (34.3)15 (46.9)
    Histology
    Ductal9865 (69.2)33 (70.2)
    Lobular1912 (12.7)7 (14.9)0.86a
    Other2417 (18.1)7 (14.9)
    Staged
    I4223 (24.7)19 (40.4)
    II8055 (59.2)25 (53.2)0.079a
    III–IV1815 (16.1)3 (6.4)
    ER statuse
    Negative4631 (34.4)15 (31.9)0.46b
    Positive9159 (65.6)32 (68.1)
    PR statuse
    Negative5031 (34.4)19 (41.3)0.27b
    Positive8659 (65.6)27 (58.7)
    PSA statusf
    Negative11985 (91.4)34 (72.3)0.004b
    Positive218 (8.6)13 (27.7)
    Adjuvant treatment
    None4126 (27.7)15 (31.9)
    Tamoxifen6546 (48.9)19 (40.4)0.63a
    Chemotherapy± tamoxifen3522 (23.4)13 (27.7)
    • a χ2 test.

    • b Fisher’s exact test.

    • c Bloom-Richardson grading system.

    • d TNM system.

    • e Cutoff point: 10 fmol/mg protein.

    • f Cutoff point: 60 ng/g protein, equal to the 75th percentile of the distribution of PSA concentrations.

  • Table 2

    Associations of TA genotypes with breast cancer survival

    VariableDFsOS
    RRa (95% CI)bPRRa (95% CI)bP
    Univariate analysis
    (TA)01.001.00
    (TA)0/(TA)9, (TA)90.50 (0.26–0.98)0.0430.53 (0.24–1.18)0.12
    Multivariate analysisc
    (TA)01.001.00
    (TA)0/(TA)9, (TA)90.58 (0.29–1.16)0.130.54 (0.24–1.23)0.14
    • a RR estimated from Cox proportional hazards regression model.

    • b CI of the estimated RR.

    • c Multivariate models were adjusted for lymph nodes status, tumor size, patient age, and ER and PR expression.

PreviousNext
Back to top
April 2000
Volume 9, Issue 4
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
TA Repeat Polymorphism of the 5α-Reductase Gene and Breast Cancer
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
TA Repeat Polymorphism of the 5α-Reductase Gene and Breast Cancer
Bhupinder Bharaj, Andreas Scorilas, Maurizia Giai and Eleftherios P. Diamandis
Cancer Epidemiol Biomarkers Prev April 1 2000 (9) (4) 387-393;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
TA Repeat Polymorphism of the 5α-Reductase Gene and Breast Cancer
Bhupinder Bharaj, Andreas Scorilas, Maurizia Giai and Eleftherios P. Diamandis
Cancer Epidemiol Biomarkers Prev April 1 2000 (9) (4) 387-393;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement